|Bid||0.0000 x 900|
|Ask||0.0000 x 1000|
|Day's Range||0.9011 - 0.9660|
|52 Week Range||0.8220 - 11.9600|
|Beta (3Y Monthly)||0.58|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Back in 2010, Nathaniel August, an activist investor, decided it was time to launch his own hedge fund, and he named it Mangrove Partners after a tree species that has the ability to survive extreme weather conditions such as storms and hurricanes. The idea behind this name was to symbolically present hedge fund that is […]
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
were crumbling Thursday, falling more than 75% after the company announced that its lung disease treatment candidate Molgradex failed its Phase 3 study. "Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint," said Rob Neville, Savara's chief executive officer. The company said that was meeting with the Food and Drug Administration and the European Medicines Agency to discuss the results of the study and to determine its next course of action.
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
crumpled in after-hours trading Wednesday after the company said a phase 3 trial of its Molgradex drug treatment for a rare lung disease had failed to meet its test goals. "Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint," said Rob Neville, Savara's chief executive officer.
Savara Inc (SVRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...
The big shareholder groups in Savara Inc. (NASDAQ:SVRA) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Read More...
The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the funds’ positions on September […]